AFP and hepatocellular carcinoma: Current guidelines recommend the screening of HCC in at-risk patients using ultrasonography (US) of the liver every 6 months with or without serum alpha-fetoprotein (AFP) [46,47], the most commonly used biomarker for liver disease detection.